Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.

Key Points VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful. Tolerability and trial design adjustments are crucial for oral VK2735's success. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) is a much-loved stock on Wall Street. It's trading at around $30 a share at the time of this writing, but the analyst consensus target price on Visible Alpha is $90.89, with nine brokers rating it the equivalent of a buy and only one with a neutral rating on the stock.